LENZ Therapeutics, Inc. LENZ
3.92
0.20
5.38%
as of 25 Sep
- Market cap
- $117.4M
- P/E
- 0.0×
Follow LENZ
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (59.21%) | (49.71%) | (33.63%) | (28.78%) |
+8 more TTM periods Free account |
|
| (55.52%) | (46.01%) | (31.52%) | (27.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(58.05%) | (44.73%) | (29.18%) | (30.68%) | |
Average Days of Receivables |
7.51 | 5.96 | 0.00 | — | |
Free Cash Flow per Share |
(3.65) | (2.79) | (2.43) | (1.62) | |
Free Cash Flow |
(114.42) | (87.44) | (70.00) | (46.16) | |
Capital Expenditures |
(0.51) | (0.73) | (0.83) | (0.94) | |
Piotroski F-Score |
3.00 | 4.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(25.93%) | (17.17%) | (11.99%) | (11.42%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.90 | 0.85 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
570.41 | 644.02 | 0.00 | 0.00 | |
Days of Inventory on Hand |
353.59 | 206.13 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
705.78% | 595.48% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
74.22% | 68.18% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | 0.80 | 0.84 | 0.77 | |
Depreciation/Fixed assets |
0.45 | 0.33 | 0.24 | 0.16 | |
Capex/Depreciation |
(1.13) | (2.03) | (2.88) | (4.58) | |
Revenue per Share |
0.68 | 0.67 | 0.00 | 0.00 | |
Operating CF per Share |
(3.63) | (2.77) | (2.40) | (1.58) | |
Capex per Share |
(0.02) | (0.02) | (0.03) | (0.03) | |
Capex to Sales |
0.02 | 0.04 | 0.00 | 0.00 | |
Net Profit Margin |
(586.74%) | (519.30%) | 0.00% | 0.00% |
Columns are period end dates